• Amyloid Beta-peptide (25-35): Precision Tools for Microglial

  2026-05-09

  Discover how Amyloid Beta-peptide (25-35) (Aβ25-35) enables advanced investigation of microglial polarization and neuroinflammation in Alzheimer's disease models. This article delivers a unique perspective on leveraging Aβ25-35 for dissecting immune-neural interactions and optimizing neurodegenerative disease research.

• Targeting Dlat-Trpv3 Signaling to Enhance Adipose Thermogene

  2026-05-08

  This study reveals that hyperforin stimulates adipose thermogenesis through a non-canonical Dlat-Trpv3-Ca2+-AMPK pathway, offering an alternative to β3-adrenergic receptor targeting for anti-obesity therapy. Findings indicate oral hyperforin is effective and safe, highlighting new mechanistic opportunities for metabolic disease intervention.

• Ganoderma lucidum Polysaccharide Enhances mRNA-LNP Efficacy

  2026-05-08

  A recent study demonstrates that Ganoderma lucidum polysaccharide (GLP) can be co-formulated with mRNA-lipid nanoparticles (LNPs) to alleviate oxidative stress and substantially improve mRNA transfection efficiency both in vitro and in vivo. This dual-action approach addresses longstanding challenges in mRNA delivery, with implications for vaccine development and molecular biology assays.

• Re-examining Sumatriptan Metabolism: CYP and MAO Pathways Un

  2026-05-07

  This study systematically revisits the metabolism of sumatriptan, challenging the prevailing view that monoamine oxidase A (MAO A) is the exclusive pathway for its biotransformation. Using recombinant human enzymes and HPLC-MS, the authors demonstrate that cytochrome P450 (CYP) isoforms also contribute to sumatriptan's demethylation, offering nuanced insight into serotonergic drug metabolism and implications for neuropharmacological research.

• Mechanistic Innovation: (R,S)-Anatabine in Neurodegeneration

  2026-05-07

  (R,S)-Anatabine, a minor tobacco alkaloid and potent amyloid-beta pathway modulator, is redefining experimental approaches in Alzheimer's disease research. This article unpacks the mechanistic underpinnings of (R,S)-Anatabine, positions it in the competitive translational research landscape, and offers strategic guidance for leveraging its unique properties in both in vitro and in vivo Alzheimer's disease models. Drawing on the latest mechanistic research and contextualizing breakthroughs from adjacent fields such as skin barrier biology, we chart a path for forward-thinking researchers seeking to accelerate therapeutic innovation.

• AP20187: Chemical Inducer of Dimerization for Gene Control

  2026-05-06

  AP20187 is a synthetic, cell-permeable chemical inducer of dimerization enabling precise and reversible control of engineered fusion protein activity in conditional gene expression systems. Its high solubility and validated in vivo efficacy make it a cornerstone reagent for regulated cell therapy and metabolic pathway research.

• LY2886721 and the Thresholds of BACE1 Inhibition in Alzheime

  2026-05-06

  Explore the nuanced role of LY2886721 as a potent BACE inhibitor in Alzheimer's disease treatment research. This article uniquely examines dose-dependent effects on amyloid beta reduction and synaptic safety, offering advanced insight for translational assay design.

• LY-411575: Gamma-Secretase Inhibitor for Advanced Disease Mo

  2026-05-05

  LY-411575 is a potent and selective gamma-secretase inhibitor that enables precise modulation of amyloid beta production and Notch signaling in Alzheimer's and cancer research. This guide distills real-world workflows, troubleshooting strategies, and data-driven insights to help researchers achieve reproducible results across both in vitro and in vivo models.

• Prochlorperazine: Dopamine D2 Antagonist for Cancer & Virolo

  2026-05-05

  Prochlorperazine’s unique multi-receptor profile unlocks advanced workflows in both melanoma research and antiviral screening. This guide details reproducible protocols, optimization tactics, and troubleshooting strategies, with insights from translational literature and APExBIO’s validated supply chain.

• Ampicillin Sodium: β-Lactam Antibiotic for Advanced Research

  2026-05-04

  Ampicillin sodium stands out as a gold-standard β-lactam antibiotic for antibacterial activity assays, recombinant protein production, and resistance studies due to its high purity and well-characterized mechanism. This article delivers a workflow-centric guide, highlighting protocol parameters, troubleshooting strategies, and translational insights that enable researchers to leverage APExBIO’s Ampicillin sodium for reproducible, high-impact results.

• EZ Cap™ Human PTEN mRNA: Enhanced Protocols for Tumor Suppre

  2026-05-04

  EZ Cap™ Human PTEN mRNA from APExBIO enables robust, immune-evasive restoration of PTEN for cancer and gene therapy research. This article translates cutting-edge findings in HA-LNP delivery and Cap 1 mRNA design into actionable workflows, troubleshooting tips, and future perspectives for tumor suppressor gene studies.

• 2-APB in Calcium Signaling: Protocols and Troubleshooting Ti

  2026-05-03

  2-APB (2-aminoethoxydiphenyl borate) is a powerful tool for dissecting intracellular calcium signaling, autophagy, and apoptosis, especially under stress conditions such as starvation. This article outlines practical assay enhancements, protocol parameters, and troubleshooting strategies, building on recent breakthroughs and highlighting APExBIO's trusted supply of high-quality 2-APB.

• BODIPY 581/591 C11: Advanced Ratiometric Probe for Lipid Per

  2026-05-02

  BODIPY 581/591 C11 empowers researchers with precise, ratiometric lipid peroxidation detection in live cells and membranes, enabling robust antioxidant capacity evaluation. Its red-to-green fluorescence shift streamlines oxidative stress measurement and troubleshooting, particularly for ferroptosis and disease modeling.

• β-Blocker Selectivity and Hematopoietic Regeneration Post-HC

  2026-05-01

  This study demonstrates that nonselective β-adrenergic receptor inhibitors impair hematopoietic regeneration after hematopoietic cell transplantation (HCT) in mice and humans, while β1-selective blockade does not. These findings have significant implications for post-transplant pharmacology, highlighting the importance of receptor selectivity in β-blocker therapy during hematopoietic recovery.

• LY2886721: Precision BACE Inhibition and Synaptic Safety in

  2026-05-01

  Explore the nuanced role of the BACE inhibitor LY2886721 in Alzheimer’s disease treatment research, focusing on synaptic safety and practical assay design. This article unveils key evidence and actionable guidance for researchers seeking to balance amyloid beta reduction with neural function preservation.

16165 records 1/1078 page Next 12345 下5页 Last page